All for Joomla All for Webmasters

Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study

Rate this item
(0 votes)

Utility:

First paper in which HMGCR was used in a routine testing scheme to provide a differential diagnosis of IIM. The potential cost savings (both health and lab economics) for including the testing of anti-HMGCR antibodies was included in the discussion. The highest prevalence of anti-HMGCR antibodies was found in patients with IMNM (31/69, 44.9%) and have a high disease specificity of 99.7%. The prevalence of anti-HMCGR antibodies in IIM patients from different geographies was statistically different, the highest in Canada (1/7, 14.3%e) and France (17/174, 9.8%). The prevalence and titier of anti-HMCGR antibodies was significantly higher in statin users (26.3%, 47.1 units) vs. non-statin users (3.4%, 7.3 units).
Read 246 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection